Share-based Payment Arrangement, Expense of RECURSION PHARMACEUTICALS, INC. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
RECURSION PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • RECURSION PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $25,044,000, a 41% increase year-over-year.
  • RECURSION PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $116,725,000, a 80% increase year-over-year.
  • RECURSION PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $79,501,000, a 54% increase from 2023.
  • RECURSION PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $51,679,000, a 92% increase from 2022.
  • RECURSION PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $26,872,000, a 94% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

RECURSION PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $116,725,000 $25,044,000 +$7,301,000 +41% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $109,424,000 $25,801,000 +$9,843,000 +62% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $99,581,000 $35,589,000 +$20,080,000 +129% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $79,501,000 $30,291,000 +$14,613,000 +93% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $64,888,000 $17,743,000 +$1,401,000 +8.6% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $63,487,000 $15,958,000 +$4,571,000 +40% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $58,916,000 $15,509,000 +$7,237,000 +87% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $51,679,000 $15,678,000 +$8,304,000 +113% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $43,375,000 $16,342,000 +$7,689,000 +89% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $35,686,000 $11,387,000 +$5,886,000 +107% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $29,800,000 $8,272,000 +$2,928,000 +55% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $26,872,000 $7,374,000 +$3,315,000 +82% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 $23,557,000 $8,653,000 +$5,557,000 +179% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $18,000,000 $5,501,000 +$524,000 +11% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $17,476,000 $5,344,000 +$3,646,000 +215% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $13,830,000 $4,059,000 +$3,081,000 +315% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $10,749,000 $3,096,000 +$2,272,000 +276% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $8,477,000 $4,977,000 +$4,208,000 +547% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $4,269,000 $1,698,000 +$433,000 +34% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $3,836,000 $978,000 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
Q3 2020 $824,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $769,000 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $1,265,000 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1

RECURSION PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $79,501,000 +$27,822,000 +54% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $51,679,000 +$24,807,000 +92% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $26,872,000 +$13,042,000 +94% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 $13,830,000 +$9,994,000 +261% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $3,836,000 +$2,451,000 +177% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 $1,385,000 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.